EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test

Alice Y Guh iD, Scott Fridkin, Dana Goodenough iD, Lisa G Winston, Helen Johnston, Elizabeth Basiliere iD, Danyel Olson, Christopher D Wilson, Jasmine J Watkins, Lauren Korhonen iD, Dale N Gerding iD

Infection Control & Hospital Epidemiology · 2024

DOI: 10.1017/ice.2023.262 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Infection Control & Hospital Epidemiology, 2024. Verfasst von Alice Y Guh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: Clostridioides difficile, Bacterial Toxins, Clostridium Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients tested for Clostridioides difficile infection (CDI) using a 2-step algorithm with a nucleic acid amplification test (NAAT) followed by toxin assay are not reported to the National Healthcare Safety Network as a laboratory-identified CDI event if they are NAAT positive (+)/toxin negative (−). We compared NAAT+/toxin− and NAAT+/toxin+ patients and identified factors associated with CDI treatment among NAAT+/toxin− patients.

Design

Retrospective observational study.

Setting

The study was conducted across 36 laboratories at 5 Emerging Infections Program sites. Patients: We defined a CDI case as a positive test detected by this 2-step algorithm during 2018–2020 in a patient aged ≥1 year with no positive test in the previous 8 weeks.

Methods

We used multivariable logistic regression to compare CDI-related complications and recurrence between NAAT+/toxin− and NAAT+/toxin+ cases. We used a mixed-effects logistic model to identify factors associated with treatment in NAAT+/toxin− cases.

Results

Of 1,801 cases, 1,252 were NAAT+/toxin−, and 549 were NAAT+/toxin+. CDI treatment was given to 866 (71.5%) of 1,212 NAAT+/toxin− cases versus 510 (95.9%) of 532 NAAT+/toxin+ cases ( P < .0001). NAAT+/toxin− status was protective for recurrence (adjusted odds ratio [aOR], 0.65; 95% CI, 0.55–0.77) but not CDI-related complications (aOR, 1.05; 95% CI, 0.87–1.28). Among NAAT+/toxin− cases, white blood cell count ≥15,000/µL (aOR, 1.87; 95% CI, 1.28–2.74), ≥3 unformed stools for ≥1 day (aOR, 1.90; 95% CI, 1.40–2.59), and diagnosis by a laboratory that provided no or neutral interpretive comments (aOR, 3.23; 95% CI, 2.23–4.68) were predictors of CDI treatment.

Conclusion

Use of this 2-step algorithm likely results in underreporting of some NAAT+/toxin− cases with clinically relevant CDI. Disease severity and laboratory interpretive comments influence treatment decisions for NAAT+/toxin− cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileBacterial ToxinsClostridium InfectionsHumansEnterotoxinsNucleic Acid Amplification TechniquesAlgorithms

Substanzen

Bacterial ToxinsEnterotoxins

Autor:innen und Institutionen

  • Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Emory University School of Medicine, Atlanta, Georgia.
  • Georgia Emerging Infections Program, Decatur, Georgia.
  • Atlanta Veterans' Affairs Medical Center, Decatur, Georgia.
  • University of California, San Francisco, School of Medicine, San Francisco, California.
  • Colorado Department of Public Health and Environment, Denver, Colorado.

ORCID-Profile: Alice Y Guh, Dana Goodenough, Elizabeth Basiliere, Lauren Korhonen, Dale N Gerding

Förderung

  • Intramural CDC HHS

Zitieren

APA

Guh, A. Y., Fridkin, S., Goodenough, D., Winston, L. G., Johnston, H., Basiliere, E., Olson, D., Wilson, C. D., Watkins, J. J., Korhonen, L., & Gerding, D. N. (2024). Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test. Infection Control & Hospital Epidemiology. https://doi.org/10.1017/ice.2023.262

Vancouver

Guh AY, Fridkin S, Goodenough D, Winston LG, Johnston H, Basiliere E, et al. Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test. Infection Control & Hospital Epidemiology. 2024. doi:10.1017/ice.2023.262

BibTeX
@article{Guh2024,
  author = {Guh, Alice Y and Fridkin, Scott and Goodenough, Dana and Winston, Lisa G and Johnston, Helen and Basiliere, Elizabeth and Olson, Danyel and Wilson, Christopher D and Watkins, Jasmine J and Korhonen, Lauren and Gerding, Dale N},
  title = {Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test},
  journal = {Infection Control & Hospital Epidemiology},
  year = {2024},
  doi = {10.1017/ice.2023.262}
}
Kostenlos starten →